Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 6/20 | 0.34 |
| ▸ | MAPT | P10636 | 2/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6544355 | 0.92 | ALDH1A1 (0.34) | ALDH1A1LMNALCKMAPTNPC1 | |
| SCHEMBL6544361 | 0.92 | ALDH1A1 (0.34) | ALDH1A1LMNALCKMAPTNPC1 | |
| SCHEMBL3244124 | 0.87 | MEN1 (0.42) | LMNAMAPTNPC1RAB9A | |
| SCHEMBL27939756 | 0.87 | KMT2A (0.39) | ALDH1A1LMNAMAPTNPC1RAB9A | |
| SCHEMBL3241737 | 0.86 | MEN1 (0.38) | ALDH1A1LMNAMAPTNPC1RAB9A | |
| SCHEMBL6543834 | 0.85 | NR1H4 (0.35) | ALDH1A1LMNAMAPTNPC1RAB9A | |
| SCHEMBL3245632 | 0.84 | MEN1 (0.42) | ALDH1A1LMNAMAPTNPC1RAB9A | |
| SCHEMBL27782510 | 0.84 | RAB9A (0.33) | ALDH1A1LMNAMAPTNPC1RAB9A | |
| SCHEMBL3245548 | 0.84 | LCK (0.35) | LCK | |
| SCHEMBL3487495 | 0.83 | ALDH1A1 (0.41) | ALDH1A1LMNAMAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130183297-A1 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2013-07-18 | — | — | US | disclosed |
| US-20120263716-A1 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-10-18 | — | — | US | disclosed |
| US-20120258991-A1 | METHOD OF TREATING A CANCER BY ADMINISTERING A SPECIFIED DRUG | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-10-11 | — | — | US | disclosed |
| US-8263631-B2 | Anti-cancer pharmaceutical compositions and methods for treating patients with cancer | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2012-09-11 | — | — | US | disclosed |
| EP-1167366-B1 | AMINE DERIVATIVES | DAIICHI SANKYO CO LTD (JP) | 2010-05-05 | — | — | EP | disclosed |
| US-20090028868-A1 | Anti-cancer pharmaceutical compositions and methods for treating patients with cancer | DAIICHI SANKYO COMPANY, LIMITED (JP) | 2009-01-29 | — | — | US | disclosed |
| EP-1982718-A1 | ANTI-CANCER PHARMACEUTICAL COMPOSITION | Daiichi Sankyo Company, Limited (JP) | 2008-10-22 | — | — | EP | disclosed |
| CN-1162427-C | Amine derivatives compounds | ������������ʽ���� | 2004-08-18 | — | — | CN | disclosed |
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2004-01-01 | — | — | US | disclosed |
| US-6596751-B2 | An insulin resistance improving agent, hypoglycemic agent, immunoregulatory agent, aldose reductase inhibitor, 5-lipoxygenase inhibitor, peroxidized lipid production suppressor, PPAR. activator, leukotriene antagonist, adipose | SANKYO COMPANY LIMITED (JP) | 2003-07-22 | — | — | US | disclosed |
| US-6562849-B1 | Amine compound or pharmacologically acceptable salt thereof. These compounds are useful in the treatment and/or prophylaxis of diseases such as diabetes, hyperlipemia, arteriosclerosis, cancer, etc. | SANKYO COMPANY, LIMITED (JP) | 2003-05-13 | — | — | US | disclosed |
| US-20030078426-A1 | Amine derivative compounds | SANKYO COMPANY, LIMITED (JP) | 2003-04-24 | — | — | US | disclosed |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SANKYO COMPANY, LIMITED (JP) | 2003-04-10 | — | — | US | disclosed |
| CN-1354750-A | Amine derivatives compounds | SANKYO CO (JP) | 2002-06-19 | — | — | CN | disclosed |
| EP-1167366-A1 | AMINE DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
| EP-1167357-A1 | ALPHA-SUBSTITUTED CARBOXYLIC ACID DERIVATIVES | Sankyo Company, Limited (JP) | 2002-01-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040002512-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | ALDH1A1 28/4885LMNA 3499/4885LCK 4392/4885 |
| US-20120258991-A1 | METHOD OF TREATING A CANCER BY ADMINISTERING A SPECIFIED DRUG | RNASE1, MCL1, EWSR1 | ALDH1A1 131/4885LMNA 1051/4885LCK 1941/4885 |
| US-20120263716-A1 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD | EGFR, ABL1, ERBB2 | ALDH1A1 709/4885LMNA 3089/4885LCK 23/4885 |
| US-20030069294-A1 | Alpha-substituted carboxylic acid derivatives | SLC5A1, SLC2A1, GPR119 | ALDH1A1 28/4885LMNA 3499/4885LCK 4392/4885 |
| US-20090028868-A1 | Anti-cancer pharmaceutical compositions and methods for treating patients with cancer | EGFR, ERBB2, KDR | ALDH1A1 2596/4885LMNA 2888/4885LCK 125/4885 |
| US-20030078426-A1 | Amine derivative compounds | H1-10, APOB, PRMT1 | ALDH1A1 874/4885LMNA 1519/4885LCK 1329/4885 |
| US-20130183297-A1 | METHOD OF TREATING CANCERS AND A PHARMACEUTICAL COMPOSITION THAT MAY BE USED IN PRACTICING SAID METHOD | EGFR, ABL1, ERBB2 | ALDH1A1 709/4885LMNA 3089/4885LCK 23/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.